Amgen Financial Statements (AMGN)
|
|
|
|
Report date
|
|
|
09.02.2021 |
16.02.2022 |
31.12.2022 |
09.02.2023 |
14.02.2024 |
|
31.10.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
25 424 |
25 979 |
26 323 |
26 323 |
28 190 |
|
32 620 |
|
Operating Income, bln rub |
|
|
5 794 |
6 005 |
9 566 |
5 335 |
7 897 |
|
6 750 |
|
EBITDA, bln rub |
? |
|
12 929 |
12 542 |
8 752 |
12 093 |
12 235 |
|
12 911 |
|
Net profit, bln rub |
? |
|
7 264 |
5 893 |
6 552 |
6 552 |
6 717 |
|
4 209 |
|
|
OCF, bln rub |
? |
|
10 497 |
9 261 |
9 721 |
9 721 |
8 471 |
|
9 178 |
|
CAPEX, bln rub |
? |
|
608.0 |
880.0 |
936.0 |
936.0 |
1 112 |
|
963.0 |
|
FCF, bln rub |
? |
|
9 889 |
8 381 |
8 785 |
8 785 |
7 359 |
|
8 215 |
|
Dividend payout, bln rub
|
|
|
3 755 |
4 013 |
0.000 |
4 196 |
4 556 |
|
3 627 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
51.7% |
68.1% |
0.00% |
64.0% |
67.8% |
|
86.2% |
|
|
OPEX, bln rub |
|
|
10 126 |
10 381 |
10 351 |
10 351 |
11 878 |
|
12 888 |
|
Cost of production, bln rub |
|
|
6 159 |
6 454 |
6 406 |
6 406 |
8 451 |
|
12 982 |
|
R&D, bln rub |
|
|
4 207 |
4 819 |
4 434 |
4 434 |
4 784 |
|
5 687 |
|
Interest expenses, bln rub |
|
|
1 262 |
1 197 |
1 406 |
1 406 |
2 875 |
|
3 216 |
|
|
Assets, bln rub |
|
|
62 948 |
61 165 |
65 121 |
65 121 |
97 154 |
|
90 883 |
|
Net Assets, bln rub |
? |
|
9 409 |
6 700 |
3 661 |
3 661 |
6 232 |
|
7 527 |
|
Debt, bln rub |
|
|
32 986 |
33 309 |
38 945 |
38 945 |
64 613 |
|
60 398 |
|
Cash, bln rub |
|
|
10 647 |
8 037 |
9 305 |
9 305 |
10 944 |
|
9 011 |
|
Net debt, bln rub |
|
|
22 339 |
25 272 |
29 640 |
29 640 |
53 669 |
|
51 387 |
|
|
Ordinary share price, rub |
|
|
229.9 |
225.0 |
262.6 |
262.6 |
288.0 |
|
268.0 |
|
Number of ordinary shares, mln |
|
|
586.0 |
570.0 |
538.0 |
538.0 |
535.0 |
|
537.0 |
|
|
Market cap, bln rub |
|
|
134 733 |
128 233 |
141 300 |
141 300 |
154 091 |
|
143 927 |
|
EV, bln rub |
? |
|
157 072 |
153 505 |
170 940 |
170 940 |
207 760 |
|
195 314 |
|
Book value, bln rub |
|
|
-21 867 |
-23 372 |
-27 948 |
-27 948 |
-45 038 |
|
-40 051 |
|
|
EPS, rub |
? |
|
12.4 |
10.3 |
12.2 |
12.2 |
12.6 |
|
7.84 |
|
FCF/share, rub |
|
|
16.9 |
14.7 |
16.3 |
16.3 |
13.8 |
|
15.3 |
|
BV/share, rub |
|
|
-37.3 |
-41.0 |
-51.9 |
-51.9 |
-84.2 |
|
-74.6 |
|
|
EBITDA margin, % |
? |
|
50.9% |
48.3% |
33.2% |
45.9% |
43.4% |
|
39.6% |
|
Net margin, % |
? |
|
28.6% |
22.7% |
24.9% |
24.9% |
23.8% |
|
12.9% |
|
FCF yield, % |
? |
|
7.34% |
6.54% |
6.22% |
6.22% |
4.78% |
|
5.71% |
|
ROE, % |
? |
|
77.2% |
88.0% |
179.0% |
179.0% |
107.8% |
|
55.9% |
|
ROA, % |
? |
|
11.5% |
9.63% |
10.1% |
10.1% |
6.91% |
|
4.63% |
|
|
P/E |
? |
|
18.5 |
21.8 |
21.6 |
21.6 |
22.9 |
|
34.2 |
|
P/FCF |
|
|
13.6 |
15.3 |
16.1 |
16.1 |
20.9 |
|
17.5 |
|
P/S |
? |
|
5.30 |
4.94 |
5.37 |
5.37 |
5.47 |
|
4.41 |
|
P/BV |
? |
|
-6.16 |
-5.49 |
-5.06 |
-5.06 |
-3.42 |
|
-3.59 |
|
EV/EBITDA |
? |
|
12.1 |
12.2 |
19.5 |
14.1 |
17.0 |
|
15.1 |
|
Debt/EBITDA |
|
|
1.73 |
2.01 |
3.39 |
2.45 |
4.39 |
|
3.98 |
|
|
R&D/CAPEX, % |
|
|
691.9% |
547.6% |
473.7% |
473.7% |
430.2% |
|
590.6% |
|
|
CAPEX/Revenue, % |
|
|
2.39% |
3.39% |
3.56% |
3.56% |
3.94% |
|
2.95% |
|
| Amgen shareholders |
